Frontlight ResearchEarly access
Active, not recruitingPhase 2
CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
Key facts
- Who runs it
- Cascade Pharmaceuticals, Inc
- Where
- China11 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Started
- 7 Aug 2023
- Ended
- May 2026
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- CS0159
- Record updated
- 13 March 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 34 criteriaShow less
Who can take part
- Male or female age≥18 or age≤75 years when sign ICF
- Within the last year, have a clinical diagnosis of PSC with a consistent magnetic resonance cholangiopancreatography (MRCP) orendoscopic retrograde cholangiopancreatography (ERCP) Prcutaneous Transhepatic Cholangiography(PTC) showing sclerosing cholangitis
- 1.50×ULN≤ALP≤10×ULN, and TBil≤3×ULN during screen
- Taken UDCA(≤25mg/kg/d)≥6 months before randomization and stable does≥ 3 months, or not used UDCA≥3 months before randomization
- For subject with a history of IBD; Patients with Crohn's Disease (CD),Must be in remission, CDAI<150 or CDAI of score ≤4; Patients with(Ulcerative Colitis)UC,Must be in remission or only mild activity,Some Mayo scores range from 0 to 4
- Be able to understand and Comply with the study protocol sign a written informed consent form(ICF)voluntarily
Who cannot take part
- Taken( ObeticholicAcid) OCA within 3 months before randomization
- Acute cholangitis was suspected or confirmed within 3 months prior to randomization, Including acute cholangitis being treated during screening
- Known concurrent comorbidities with other hepatobiliary diseases including, but not limited to: active hepatitis B virus or hepatitis C virus infection (see Exclusion Criterion 9), primary biliary cholangitis, complete biliary obstruction, acute cholecystitis or gallstones with significant symptoms, Autoimmune Hepatitis (AIH) or overlap with other autoimmune liver diseases, Alcoholic Hepatitis, Non-Alcoholic Steatohepatitis, Suspected or Diagnosed Primary Hepatocellular Cancer, and Bile Duct Cancer
- Severe pruritus may require systemic medication Within 2 months prior to randomization
- A disease that interferes with the absorption, distribution, metabolism, or excretion of a test drug,such as moderate to severe activity IBD patient, Previous gastric bypass surgery
- Moderate or intense inhibition of CYP3A4 was performed during 14 days prior to randomization and throughout the trial Preparation or inducer
- Immunosuppressants, budesonide, and other systemic glucocorticoids were used within 28 days before randomization and throughout the clinical study period
- Use of fenofibrate or another fibrate within 28 days prior to randomization and throughout the clinical study period; Hepatotoxic drugs; Hepatoprotective drugs and other hepatoprotective drugs were given stable doses <28 days before randomization or could not maintain stable doses during the trial; cholagogue
- Interleukin or other cytokines were used 12 months before randomization and throughout the trial Or antibodies to chemokines or immunotherapy
- Drug and/or alcohol abuse within the first six months of randomization
- Participated any other study within 30 days prior randomization,and received other experimental medications therapy
- Child-Pugh patients with grade B or C cirrhosis,Present complications related to cirrhosis or End-stage liver disease ,Including history of liver transplantation Preparing for liver transplantation (Model for End-Stage Liver Disease)MELD≥15,Portal hypertension complications,Complications of cirrhosis
- The presence of diseases that may cause non-hepatic elevation of ALP (e.g. Paget's disease) or may cause it Diseases with a life expectancy of less than 2 years
- History of malignancy within the past 5 years prior to randomization
- It is unsuitable to participate for the study or has other diseases by the investigator
- Presence of documented secondary sclerosing cholangitis when screening,or direct evidence IgG4 related sclerosing cholangitis or serum IgG4 ≥ 4 ×ULN
- ALT or AST>5×ULN
- Cr(Creatinine)≥1.5×ULN also Cr(Creatinine)clearance rate<60 mL/min
- PLT(Platelet)<80×10\^9/L
- INR(international normalized ratio)>1.3
- Arrhythmia,male QTc≥450 ms,female QTc≥470 ms, during screening
- Poor blood sugar control,Glycated hemoglobin>9.0%
- Small duct PSC
- Presence of percutaneous drain or bile duct stent at the time of screening or during the study
- Patients who are HBsAg-positive, HCVAb-positive, HIVAb-positive or TPAb-positive at screening
- ALB<3.5g/dL
- Poor blood pressure control,systolic pressure>160 mmHg or dpb >100 mmHg
- Females who are pregnant or plan to pregnant,Fertile but refusing to sign informed consent, or breastfeed
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A phase II Study of CS0159 in Chinese patients with PSC(Primary Sclerosing Cholangitis)
The 3 groups in the trial
- 2mg CS0159Treatment being tested
CS0159 tablet 2mg for 12 weeks
Treatment: CS0159
- 4mg CS0159Treatment being tested
CS0159 tablet 4mg for 12 weeks
Treatment: CS0159
- PlaceboPlacebo, for comparison
Placebo for 12 weeks
Treatment: CS0159
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II Study to Evaluate Safety, Tolerability and Efficacy, of CS0159 in Patients Subjects With Primary Sclerosing Cholangitis, Multicenter, Randomized, 12-week Double-blind, Placebo-controlled, and 40-week Open Study
- Record updated
- 13 March 2026